Metabolism open最新文献

{"title":"Independent predictive role of nutritional markers in kidney function decline and mortality in diabetes","authors":"Tomohito Gohda ,&nbsp;Nozomu Kamei ,&nbsp;Marenao Tanaka ,&nbsp;Masato Furuhashi ,&nbsp;Tatsuya Sato ,&nbsp;Mitsunobu Kubota ,&nbsp;Michiyoshi Sanuki ,&nbsp;Risako Mikami ,&nbsp;Koji Mizutani ,&nbsp;Yusuke Suzuki ,&nbsp;Maki Murakoshi","doi":"10.1016/j.metop.2025.100386","DOIUrl":"10.1016/j.metop.2025.100386","url":null,"abstract":"<div><h3>Background</h3><div>Malnutrition and chronic inflammation are common in chronic kidney disease (CKD) and contribute to disease progression and mortality. While the prognostic nutritional index (PNI), geriatric nutritional risk index (GNRI), and controlling nutritional status (CONUT) scores assess nutritional status, their predictive values for CKD progression and mortality in individuals with diabetes, particularly independent of tumor necrosis factor receptor 2 (TNFR2), remains unclear. This study aimed to evaluate whether these markers predict outcomes beyond TNFR2.</div></div><div><h3>Subjects/methods</h3><div>We analyzed 640 individuals with diabetes, stratified by PNI quartiles (Q1 vs. Q2–4). Serum TNFR2 was measured using enzyme-linked immunosorbent assay. Nutritional status was assessed using PNI, GNRI, and CONUT scores. Cox proportional hazards models adjusted for covariates including TNFR2 examined associations between nutritional markers and a kidney event (≥30 % decline in estimated glomerular filtration rate), mortality, and a composite outcome.</div></div><div><h3>Results</h3><div>The mean age was 65 years; 53.9 % were male. Over median follow-ups of 5.3 and 5.4-years, 75 (11.7 %) experienced a kidney event and 44 (6.9 %) died. A total of 112 (17.5 %) experienced the composite outcome. All three markers were independently associated with a kidney event (PNI: hazard ratio [HR], 1.84; 95 % confidence interval [CI], 1.13–3.02) and a composite outcome (PNI: HR, 1.94; 95 % CI, 1.30–2.89). GNRI was the only marker independently associated with mortality (HR, 2.90; 95 % CI, 1.56–5.37).</div></div><div><h3>Conclusions</h3><div>PNI, GNRI, and CONUT scores strongly predict adverse outcomes in diabetes, emphasizing the importance of nutritional evaluation. Targeted nutritional interventions may improve prognosis.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"27 ","pages":"Article 100386"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145007660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of dapagliflozin on eGFR slope in IgA nephropathy based on renal pathological assessment using image analysis software","authors":"Akira Mima,&nbsp;Takahiro Nakamoto,&nbsp;Keishi Matsumoto,&nbsp;Yuta Saito,&nbsp;Takaaki Morikawa,&nbsp;Shinji Lee","doi":"10.1016/j.metop.2025.100392","DOIUrl":"10.1016/j.metop.2025.100392","url":null,"abstract":"<div><h3>Introduction</h3><div>Studies have examined the effect of dapagliflozin, a sodium-glucose co-transporter-2 (SGLT2) inhibitor, on chronic kidney disease (CKD), including immunoglobulin A nephropathy (IgAN). Dapagliflozin decreases albuminuria and slows the decline in estimated glomerular filtration rate (eGFR). However, its renoprotective effects may not be observed in all patients with IgAN in real-world clinical practice. In this study, we aimed to investigate the potential relationship between renal histopathology analyzed using imaging software and the renoprotective effects of dapagliflozin.</div></div><div><h3>Methods</h3><div>The mesangial matrix fraction (Mes Fx) in patients with IgAN was analyzed using Image-J, an imaging software. The relationships between eGFR slope decline, changes in urinary protein, and the degree of Mes Fx before and after dapagliflozin treatment were investigated.</div></div><div><h3>Results</h3><div>A significant correlation was evident between the degree of Mes Fx and eGFR slope decline in patients with IgAN. Furthermore, it was suggested that when the Mes Fx exceeded 10 % of the total glomerular surface area, the effect of dapagliflozin in slowing the eGFR decline was unclear.</div></div><div><h3>Conclusions</h3><div>However, it should be noted that this study has limitations, including the absence of a control group, the small data size, and its pilot study nature. Therefore, it cannot be stated unequivocally that dapagliflozin's efficacy is definitively demonstrated by Mes Fx predictive role.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"28 ","pages":"Article 100392"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145020548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Selective serotonin reuptake inhibitors and glucose metabolism in Alzheimer's disease and related dementias: A systematic review and meta-analysis of brain metabolic and adverse event data","authors":"Faisal Alzenaidi ,&nbsp;Osama Aldoweesh ,&nbsp;Salman Alghofaili ,&nbsp;Abdulaziz Fadel ,&nbsp;Razan Ali Awad Lasloom ,&nbsp;Dhay Alharbi ,&nbsp;Faris Almalki ,&nbsp;Atheer Ahmad Alkhairi ,&nbsp;Maram Alharbi ,&nbsp;Norah Ahmed Alhamdan ,&nbsp;Ahmed Y. Azzam","doi":"10.1016/j.metop.2025.100389","DOIUrl":"10.1016/j.metop.2025.100389","url":null,"abstract":"<div><h3>Introduction</h3><div>Selective serotonin reuptake inhibitors (SSRIs) are commonly prescribed for depression in Alzheimer's disease (AD), however their effects on glucose metabolism remain poorly understood. We conducted a systematic review and meta-analysis to evaluate SSRI effects on brain glucose metabolism and metabolic adverse events in AD patients.</div></div><div><h3>Methods</h3><div>Following PRISMA 2020 guidelines, we searched multiple databases up to July 11, 2025 for studies investigating SSRI effects on glucose-related outcomes in AD patients. Despite significant heterogeneity in study designs and populations, we performed meta-analyses for adverse events and coordinate-based meta-analysis for neuroimaging data. We performed meta-analyses for adverse events and coordinate-based meta-analysis for neuroimaging data. Advanced Bayesian hierarchical modeling and Markov simulations projected long-term metabolic outcomes.</div></div><div><h3>Results</h3><div>Twelve studies with total included 7143 participants met our inclusion criteria, including nine randomized controlled trials and three observational studies. Brain FDG-PET revealed SSRI use restored dorsal raphe nucleus hypometabolism (standardized mean difference 0.87, 95 % CI: 0.52–1.22, P-value = 0.001). Meta-analysis demonstrated increased gastrointestinal adverse events (risk ratio 2.15, 95 % CI: 1.68–2.76, P-value&lt;0.001, with moderate between-study heterogeneity), with sertraline showing highest rates. Citalopram 30 mg provided significant weight loss protection (risk ratio 0.13, 95 % CI: 0.02–0.98, P-value = 0.02), though this exceeds the recommended 20 mg maximum dose for elderly patients due to cardiac safety considerations. Long-term diabetes incidence showed no increased risk (hazard ratio 0.75, 95 % CI: 0.50–1.12, P-value = 0.15). Bayesian modeling revealed 85 % probability of beneficial brain metabolic effects and 89 % probability of citalopram superiority for weight protection.</div></div><div><h3>Conclusions</h3><div>SSRIs restore brain glucose metabolism in AD patients while causing manageable peripheral metabolic effects. Citalopram appears the best for weight-sensitive patients, while sertraline requires gastrointestinal monitoring. These findings support SSRI safety for metabolic outcomes in AD treatment, however longer-term studies with controlled metabolic outcomes are needed to confirm our findings. The observed citalopram weight protection benefit was documented at 30 mg daily, which exceeds recommended dosing limits for elderly patients due to cardiac safety concerns.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"27 ","pages":"Article 100389"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144922300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Vitamin D3 supplementation in women practicing orthodox religious and intermittent fasting: A controlled study with formulation-specific effects","authors":"Spyridon N. Karras ,&nbsp;Konstantinos Michalakis ,&nbsp;Maria Kypraiou ,&nbsp;Antonios Vlastos ,&nbsp;Marios Anemoulis ,&nbsp;Georgios Koukoulis ,&nbsp;Zadalla Mouslech ,&nbsp;Filotas Talidis ,&nbsp;Costas Haitoglou ,&nbsp;Evangelos G. Papanikolaou ,&nbsp;Neoklis Georgopoulos ,&nbsp;Georgios Tzimagiorgis","doi":"10.1016/j.metop.2025.100391","DOIUrl":"10.1016/j.metop.2025.100391","url":null,"abstract":"<div><h3>Background</h3><div>Vitamin D deficiency is prevalent among monastic Orthodox populations, likely due to their sartorial habits and religious fasting rules. Data on supplementation in similar populations are lacking, including responses in restoring vitamin D sufficiency and to specific formulations of vitamin D supplements. This controlled study evaluated the efficacy of a daily oral vitamin D regimen, using oil-based drops and tablets, in restoring vitamin D status in a population of Orthodox nuns from Northern Greece, as well as assessing potential formulation-specific effects in the context of vitamin D supplementation.</div></div><div><h3>Methods</h3><div>A total of 41 Orthodox nuns practicing intermittent fasting received a daily dose of 2.500 IU vitamin D3 in either oil-based drops or tablets for 16 weeks and were compared to 40 matched controls without supplementation. Serum concentrations of 25-hydroxyvitamin D [25(OH)D], parathyroid hormone (PTH), calcium, and albumin were measured at baseline and after 16 weeks in both groups.</div></div><div><h3>Results</h3><div>In the supplemented group, mean serum 25(OH)D concentrations increased significantly from 21.44 ± 9.08 ng/mL to 34.27 ± 10.33 ng/mL (p = 0.022), while PTH decreased from 66.18 ± 21.31 pg/mL to 50.71 ± 15.92 pg/mL (p = 0.018). The control group showed no significant changes in either 25(OH)D (23.90 ± 7.11 vs. 26.53 ± 9.14 ng/mL, p = 0.067) or PTH (41.75 ± 15.74 vs. 40.11 ± 13.56 pg/mL, p = 0.415). Multivariate regression—adjusting for baseline 25(OH)D, BMI, and body fat percentage—indicated that the form of supplementation (tablet vs. drops) was not an independent predictor of the change in vitamin D concentrations (β = +2.77, p = 0.456). The only statistically significant predictor was baseline 25(OH)D (β = −0.63, p &lt; 0.001).</div></div><div><h3>Conclusions</h3><div>A daily regimen of oral vitamin D3, administered as either drops or tablets, is effective in significantly improving vitamin D status and reducing PTH concentrations in women adhering to intermittent fasting religious practices. These findings support targeted supplementation strategies in at-risk fasting populations, particularly those with vitamin D deficiency, regardless of the form of oral supplementation.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"27 ","pages":"Article 100391"},"PeriodicalIF":2.7,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144920162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Supplementary use of natural products in managing dumping syndrome: Exploring dietary and phytochemical interventions","authors":"Abdullah Al Lawati ,&nbsp;Ayman N. Alhabsi ,&nbsp;Ali Al Sabti ,&nbsp;Raksha S. Krishnan ,&nbsp;Sulaiman Alkindi ,&nbsp;Srijit Das ,&nbsp;Mohammed Al-Abri","doi":"10.1016/j.metop.2025.100387","DOIUrl":"10.1016/j.metop.2025.100387","url":null,"abstract":"<div><div>Dumping syndrome (DS) is a known complication following bariatric surgery, caused by rapid gastric emptying into the small intestine. It presents in two forms: early dumping, with gastrointestinal and vasomotor symptoms occurring within 30–60 min after meals; and late dumping, which arises 1–3 h postprandially due to reactive hypoglycaemia. Standard management includes dietary changes and medications, but tolerability and long-term efficacy are variable. Recently, interest has grown in using natural products and nutritional compounds as adjuncts or alternatives. Fibre-rich foods, sugar substitutes, and medicinal plants may delay gastric emptying, reduce glucose spikes, or modulate gut hormones such as GLP-1 and GIP. Several phytochemicals, polyphenols, flavonoids, alkaloids, and terpenoids have demonstrated promise in reducing DS symptoms, especially in late dumping. Functional foods may enhance satiety, slow carbohydrate absorption, and improve glycaemic control. Although most data are from preclinical or limited clinical studies, natural compounds appear to be well-tolerated and safe, offering potential advantages over standard pharmacological agents. This review summarises emerging evidence on the role of natural products in managing DS, their mechanisms of action, and their clinical relevance in post-bariatric care. The findings aim to support translational metabolic care and provide practical guidance for clinicians and dietitians managing DS in diverse patient populations.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"27 ","pages":"Article 100387"},"PeriodicalIF":2.7,"publicationDate":"2025-08-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144902322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between triglyceride-glucose index and all-cause mortality in older adults with sarcopenic obesity","authors":"Qiong Huang ,&nbsp;Xiuben Du ,&nbsp;Wenwei Ouyang ,&nbsp;Jing Wang ,&nbsp;Xusheng Liu","doi":"10.1016/j.metop.2025.100388","DOIUrl":"10.1016/j.metop.2025.100388","url":null,"abstract":"<div><h3>Background</h3><div>Sarcopenic obesity (SO) combines reduced muscle mass and increased fat, elevating health risks in older adults. The triglyceride-glucose (TyG) index, a marker of insulin resistance, is associated with metabolic dysfunction. However, its role in predicting mortality in SO remains unclear. This study investigates the TyG index as a potential predictor of all-cause mortality in older adults with SO.</div></div><div><h3>Methods</h3><div>This study examined SO trends using data from 30,137 adults with dual-energy X-ray absorptiometry (DXA) and body fat measurements (1999–2018). For mortality analysis, 706 participants from NHANES 1999–2004 were included. Sarcopenia was defined according to the 2014 FNIH criteria. Statistical analyses, including Cox regression, cubic splines, and subgroup analyses, were employed to investigate the association between the TyG index and all-cause mortality in SO, as well as mortality variations among NHANES participants.</div></div><div><h3>Results</h3><div>Older age groups exhibit higher SO prevalence rates, with a notable upward trend in the &gt;70 years group, while younger groups maintain lower rates. Trend analysis indicates no significant change from 1999 to 2006 but suggests a moderate, near-significant increase from 2011 to 2018. There was a U-shaped association between the TyG index and all-cause mortality. After full adjustment, adults in TyG group 1 (less than 3.25) had a 78.1 % higher risk (hazard ratio, 1.781; 95 % CI, 1.406–2.256; p &lt; 0.001), and those in TyG group 5 (6.66 or greater) had a 74.5 % higher risk (hazard ratio, 1.745; 95 % CI, 1.211–2.516; p = 0.003) compared to the reference group (TyG group 3, 4.25 to 5.25). Subgroup analysis by age revealed that, among participants aged 70 and older, the group with the lowest mortality risk transitioned from Group 3 to Group 2. Furthermore, the analysis of varying mortality reveals that Group 5 (HR: 3.088; 95 % CI: 1.462–6.520; p = 0.003) is significantly associated with an increased risk of cardiovascular disease (CVD) mortality compared to Group 3. Similarly, TyG Group 1 demonstrates a significantly higher risk of mortality from other causes (HR: 2.253; 95 % CI: 1.207–4.206; p = 0.011) relative to Group 3. No significant associations are observed for malignant neoplasms, respiratory diseases, or cerebrovascular/Alzheimer's diseases.</div></div><div><h3>Conclusion</h3><div>This national cohort study identified a U-shaped association between the TyG index and all-cause mortality among SO patients, with increased risks observed at both low and high TyG levels. Age-specific analyses further reveal variations in this relationship, underscoring the importance of tailored strategies to enhance metabolic health and reduce mortality risks.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"27 ","pages":"Article 100388"},"PeriodicalIF":2.7,"publicationDate":"2025-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144894970","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Helicobacter pylori infection and association with chronic diseases: A focus on cardiovascular disease, MASLD, and type 2 diabetes","authors":"Navid Maleki ,&nbsp;Alireza Mohammadzadeh ,&nbsp;Jalal Mardaneh ,&nbsp;Hossein Pazoki ,&nbsp;Elyas Nattagh-Eshtivani","doi":"10.1016/j.metop.2025.100385","DOIUrl":"10.1016/j.metop.2025.100385","url":null,"abstract":"<div><div><em>Helicobacter pylori</em> (<em>H. pylori</em>) infection is a globally prevalent gastrointestinal pathogen increasingly linked to various extra-gastric non-communicable diseases (NCDs). This review addresses the guiding question: What epidemiological and mechanistic links explain the association between H. pylori infection and chronic conditions such as cardiovascular disease (CVD), metabolic dysfunction-associated steatotic liver disease (MASLD), and type 2 diabetes mellitus (T2DM)?</div><div>The manuscript synthesizes evidence from epidemiological studies and mechanistic research. In CVD, <em>H. pylori</em> exacerbates chronic vascular inflammation, endothelial dysfunction, and autoimmune-like responses such as molecular mimicry. In MASLD, <em>H. pylori</em> induces insulin resistance (IR), hepatic inflammation, and microbiota-mediated liver injury, although findings remain inconclusive across populations. For T2DM, multiple pathways including NLRP3 inflammasome activation, hormonal imbalances (e.g., ghrelin, leptin), and immune-genetic interactions involving TLR4 and SOCS3 suggest a role for <em>H. pylori</em> in metabolic dysregulation and impaired glycemic control. While researchers have not yet fully elucidated causality, these findings indicate <em>H. pylori</em> as a potential modifiable risk factor for NCDs. Future longitudinal and interventional studies are warranted to determine whether eradication of <em>H. pylori</em> can mitigate chronic disease.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"27 ","pages":"Article 100385"},"PeriodicalIF":2.7,"publicationDate":"2025-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144842608","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Harmonizing gut microbiota dysbiosis: Unveiling the influence of diet and lifestyle interventions","authors":"Sharvari S. Pandit ,&nbsp;Prabhu Meganathan ,&nbsp;Hemamalini Vedagiri","doi":"10.1016/j.metop.2025.100384","DOIUrl":"10.1016/j.metop.2025.100384","url":null,"abstract":"<div><div>The gut microbiota, comprising trillions of microorganisms inhabiting the gastrointestinal tract, is essential to human health and disease. Recent research has illuminated the interactions between many components of human physiology and the gut microbiota, including immune function, metabolism, and neurological health. Central to maintaining this symbiotic relationship is the concept of dysbiosis – an imbalance in the makeup and roles of the gut microbiota. Dysbiosis of the gut microbiota has emerged as a significant factor in the pathogenesis of numerous health conditions, spanning from gastrointestinal disorders like inflammatory bowel disease and irritable bowel syndrome to systemic diseases such as obesity, metabolic syndrome, and even neurological disorders like depression and anxiety. While dysbiosis can result from a myriad of factors including antibiotic use, stress, and genetic predispositions, emerging evidence suggests that diet and lifestyle choices exert profound influences regarding the make-up and capabilities of the gut microbiota. In this review, We explore the complex interactions among lifestyle, nutrition, and gut microbial dysbiosis. In particular, we investigate how the gut microbiota can be modified and dysbiosis can be mitigated by dietary patterns, food composition, prebiotics, probiotics, and lifestyle factors including exercise, stress reduction, and good sleep hygiene. Restoring microbial balance and enhancing general health and well-being can be achieved through preventive and therapeutic measures that can be made more effective by understanding how dietary and lifestyle changes might affect the gut microbiota. Through this exploration, we aim to elucidate the possibility of using lifestyle and dietary modifications as tools for managing gut microbial dysbiosis.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"27 ","pages":"Article 100384"},"PeriodicalIF":2.7,"publicationDate":"2025-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144842610","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effectiveness of continuous glucose monitoring systems on glycemic control in adults with type 1 diabetes: A systematic review and meta-analysis","authors":"Salya F. Alfadli ,&nbsp;Yazeed S. Alotaibi ,&nbsp;Maha J. Aqdi ,&nbsp;Latifah A. Almozan ,&nbsp;Zahra B. Alzubaidi ,&nbsp;Hammad A. Altemani ,&nbsp;Shaden D. Almutairi ,&nbsp;Hussain A. Alabdullah ,&nbsp;Alaa Ahmed Almehmadi ,&nbsp;Abdulrahman L. Alanzi ,&nbsp;Ahmed Y. Azzam","doi":"10.1016/j.metop.2025.100382","DOIUrl":"10.1016/j.metop.2025.100382","url":null,"abstract":"<div><h3>Introduction</h3><div>Continuous glucose monitoring (CGM) technologies have been advancing rapidly, but evidence on their comparative effectiveness stills limited to date yet. We conducted a systematic review and meta-analysis to evaluate and investigate the impact of CGM systems on glycemic control in adults with type 1 diabetes.</div></div><div><h3>Methods</h3><div>We searched electronic literature databases from inception through April 30, 2025, for comparative studies investigating CGM systems with standard monitoring or different CGM technologies in adults with type 1 diabetes. Primary outcomes included HbA1c reduction, time in range (TIR), and hypoglycemia reduction. We performed random-effects meta-analyses, network meta-analysis, and subgroup analyses by baseline HbA1c and intervention duration. Evidence quality was assessed using GRADE methodology.</div></div><div><h3>Results</h3><div>Twenty-seven studies with total of 2975 participants were included. CGM significantly reduced HbA1c compared to standard monitoring (mean difference: 0.38 %, 95 % CI: 0.49 to −0.27 %). TIR increased by 7.9 % (95 % CI: 5.8–10.0 %), representing 114 additional minutes daily in best range. Real-time CGM showed advantages over intermittently scanned CGM for TIR (+5.63 %, P-value&lt;0.001) and hypoglycemia reduction (−1.28 %, P-value&lt;0.001). Automated closed-loop systems achieved the highest ranking in network meta-analysis (SUCRA = 0.92). Benefits were greater among patients with higher baseline HbA1c (&gt;8.5 %: 0.68 % reduction in HbA1c vs. &lt;7.5 %: 0.24 % reduction in HbA1c, P-value = 0.009).</div></div><div><h3>Conclusions</h3><div>CGM technologies significantly improve glycemic control in adults with type 1 diabetes, with greater benefits for those with higher baseline HbA1c. Advanced systems demonstrate progressively greater improvements, with automated closed-loop systems showing the strongest evidence of effectiveness. These findings support broader implementation of CGM technologies, with selection tailored to individual patient needs.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"27 ","pages":"Article 100382"},"PeriodicalIF":2.7,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144738464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Quantitative lipidomic analysis reveals distinct metabolic traits between stromal cell subpopulations in human orbital adipose tissue","authors":"Shuwei Tian ,&nbsp;Xiaoli Zhang ,&nbsp;Jiayong Yu ,&nbsp;Juan Cai ,&nbsp;Danni Wei ,&nbsp;Siqi Li ,&nbsp;Pengfei Cai ,&nbsp;Wei Song ,&nbsp;Suihan Feng ,&nbsp;Mengle Shao ,&nbsp;Haizhou Li","doi":"10.1016/j.metop.2025.100380","DOIUrl":"10.1016/j.metop.2025.100380","url":null,"abstract":"<div><div>Adipose tissue, a pivotal metabolic regulator, houses diverse stromal cell populations influencing its dynamic functions. Recent omics studies, including transcriptomics and proteomics, have revealed intricate cellular heterogeneity, yet comprehensive metabolic profiling remains limited. Leveraging fluorescence-activated cell sorting (FACS), we isolated PDGFRα+ DPP4+ and PDGFRα+ DPP4- adipose stromal cells (ASCs) from human orbital adipose tissue (OAT). Integrating gene expression analysis, in vitro adipogenesis assays, and quantitative lipidomics, we characterized their functional and metabolic distinctions. DPP4- ASCs exhibited enhanced adipogenic potential and distinct lipidomic profiles, featuring elevated ceramides and triacylglycerols compared to DPP4+ ASCs. Differential gene expression highlighted metabolic and adipogenic gene signatures reflective of their functional roles in adipose tissue remodeling. Our findings underscore the metabolic heterogeneity within OAT stromal fibroblasts, implicating DPP4- ASCs as potent regulators of adipogenesis and metabolic homeostasis. These insights enhance our understanding of adipose tissue plasticity and may inform therapeutic strategies for conditions like thyroid-associated ophthalmopathy.</div></div>","PeriodicalId":94141,"journal":{"name":"Metabolism open","volume":"27 ","pages":"Article 100380"},"PeriodicalIF":0.0,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144714460","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}